Focused Orticumab Research for Treating Inflammation in Coronary Arteries

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 240 participants.

Also called NCT06927739

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Abcentra (from the registry)
Registry
  • NCT NCT06927739
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Czechia, Hungary, Italy, Poland, Romania, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06927739. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-11 (actual); primary completion 2027-02-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
Acronym
FORTIFY
Condition
Acute Coronary Syndromes
Condition
Coronary Arterial Disease (CAD (coronary artery disease))
Condition
Inflammation
Condition
Heart Disease
Condition
Myocardial Infarct
Condition
Atherosclerotic Coronary Vascular Disease
Intervention (Drug)
Orticumab
Intervention (Drug)
Placebo
Lead sponsor
Abcentra (class: industry)

Record details

Record id
cardio:ct-nct06927739
Content hash
a530bb064d834d4046c6d7f2ce1a41aef6070ef6cef748ec1e7c472f5401d45e